China Resources Pharmaceutical Group Ltd.
3320
Classifica tra le azioni
#4247
China Resources Pharmaceutical Group Limited, an investment holding company,... China Resources Pharmaceutical Group Limited, an investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally. It operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. The company offers a range of chemical drugs, Chinese medicines, and biological drugs, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular and cerebrovascular diseases, alimentary tract, endocrine diseases, respiratory diseases, orthopedics, nephrology, rheumatology and immunology, medical nutrition, pediatrics, genitourinary system, dermatological diseases, blood products, therapeutic infusions, antitumor drugs, medicine for cough and cold, anti-infection drugs, and psychoneurosis. It also provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical/medical device manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, the company is involved in property holding activities, as well as operates retail pharmacies under the Teck Soon Hong brands. It distributes its products under the 999, Dong-E-E-Jiao, Double Crane, Zizhu, Jiangzhong, Boya, and Kun Zhong Yao to hospitals and other medical institutions. The company was formerly known as China Resources Medications Group Limited and changed its name to China Resources Pharmaceutical Group Limited in December 2011. The company was incorporated in 2007 and is based in Wan Chai, Hong Kong. China Resources Pharmaceutical Group Limited is a subsidiary of CRH (Pharmaceutical) Limited.
Prezzo delle azioni
$0.5954966
Capitalizzazione di mercato
$3.74B
Variazione (1 giorno)
1.09%
Variazione (1 anno)
-2.61%
Paese
HK
Scambia China Resources Pharmaceutical Group Ltd. (3320)
Categoria
Healthcare
Utile per China Resources Pharmaceutical Group Ltd. (3320)
Utile nel Jun 2026 TTM: $1.71B
Secondo gli ultimi rapporti finanziari di China Resources Pharmaceutical Group Ltd., gli utili attuali della società sono $1.71B. Nel 2023, la società ha registrato un utile di $1.39B, un aumento rispetto a agli utili del 2022, che erano di $1.26B. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di China Resources Pharmaceutical Group Ltd. dal 2013 al 2026
Utile alla fine di ogni anno
| Anno | Utile | Cambia |
|---|---|---|
| 2026 (TTM) | $1.71B | 13.87% |
| 2024 | $1.50B | 7.62% |
| 2023 | $1.39B | 10.35% |
| 2022 | $1.26B | 16.96% |
| 2021 | $1.08B | 18.19% |
| 2020 | $912.56M | 9.36% |
| 2019 | $834.45M | -28.83% |
| 2018 | $1.17B | 6.72% |
| 2017 | $1.10B | 5.89% |
| 2016 | $1.04B | -0.13% |
| 2015 | $1.04B | 16.37% |
| 2014 | $892.63M | 0.13% |
| 2013 | $891.51M | 0.00% |
Utile per aziende simili o concorrenti
| Azienda | Utile | Differenza negli utili | Il paese |
|---|---|---|---|
| $1.35B | -20.87% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $26.37M | -98.45% |
US
|
